Author

Alexander Schulz

Observed name: A. Schulz

Institution: Städtisches Klinikum Dessau

Observed institutions: German Cancer Research Center, Helmholtz-Zentrum Dresden-Rossendorf, Städtisches Klinikum Dessau, National Center for Tumor Diseases, Jena University Hospital, OncoRay, University Hospital Carl Gustav Carus, Nationales Centrum für Tumorerkrankungen Dresden, German Cancer Research Center (DKFZ) Dresden, Technische Universität Dresden

ORCID: 0000-0001-7499-5125

Observed ORCID: 0000-0001-7499-5125

OpenAlex ID: A5031138953

Cancer Stem Cells and Radioresistance: DNA Repair and Beyond

2019 · Alexander Schulz, Felix Meyer, et al. · Cancers · 319

Systemic Therapy of Metastatic Melanoma: On the Road to Cure

2021 · Julian Steininger, Frank Friedrich Gellrich, et al. · Cancers · 79

Role of neuropilin-2 in the immune system

2017 · S. Schellenburg, A. Schulz, et al. · Molecular Immunology · 72

Recombineering, transfection, Western, IP and ChIP methods for protein tagging via gene targeting or BAC transgenesis

2011 · Helmut Hofemeister, Giovanni Ciotta, et al. · Methods · 40

Linking NRP2 With EMT and Chemoradioresistance in Bladder Cancer

2020 · Alexander Schulz, Ielizaveta Gorodetska, et al. · Frontiers in Oncology · 35

Whole-exome sequencing in eccrine porocarcinoma indicates promising therapeutic strategies

2021 · Evgeniya Denisova, Dana Westphal, et al. · Cancer Gene Therapy · 30

Confronting Melanoma Radioresistance: Mechanisms and Therapeutic Strategies

2025 · Ielizaveta Gorodetska, Alexander Schulz, et al. · Cancers · 24

Identification of Epigenetically Regulated Genes Distinguishing Intracranial from Extracranial Melanoma Metastases

2023 · Dana Westphal, Matthias Meinhardt, et al. · Journal of Investigative Dermatology · 17

BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS ‐mutant melanoma cells: Insights into mode of action and resistance mechanisms

2023 · Lisa Dinter, Paula C. Karitzky, et al. · International Journal of Cancer · 16

Head-to-Head Comparison of BRAF/MEK Inhibitor Combinations Proposes Superiority of Encorafenib Plus Trametinib in Melanoma

2022 · Alexander Schulz, Jennifer Raetz, et al. · Cancers · 16

Silencing of Neuropilins and GIPC1 in pancreatic ductal adenocarcinoma exerts multiple cellular and molecular antitumor effects

2019 · Hannes Borchardt, Alexander Schulz, et al. · Scientific Reports · 12

De novo AHDC1 Deletions Identified by Genome Sequencing in Two Individuals with Xia-Gibbs Syndrome

2024 · Miriam Bertrand, Gulalai Shah, et al. · Molecular Syndromology · 4

Association of NRP2 and EGFR co-expression with cancer-specific survival in prostate cancer and the influence of NRP2-depletion combined with EGFR-inhibition on cell functioning in cisplatin-sensitive and –resistant DU145 prostate cancer cell lines

2018 · A. Borkowetz, S. Fuessel, et al. · European Urology Supplements

Works count: 13

Citation count: 664

H-index: 11

I10-index: 11